IP Library Granted Patent US 9,284,337
Granted Patent B2
US 9,284,337 · App. 14/353,408 · Granted Mar 15, 2016

Small molecule enhancer for dendritic cell cancer vaccines

Inventor: William W. Bachovchin (Cambridge, MA)
Assignee: Trustees of Tufts College
C07F5/025A61K31/69A61K35/17A61K38/05A61K38/20A61K38/21A61K39/0005A61K39/0011A61K45/06A61N5/10A61K2039/5154A61K2039/5158
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,284,337
App. No.
14/353,408
Granted
Mar 15, 2016
Kind
B2
Abstract

Disclosed is a method of treating cancer, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound that inhibits a plurality of mammalian dipeptidyl peptidase (DPP) IV activity and/or structural homologues thereof (DASH) serine proteases. Also disclosed is a method of (a) increasing antitumor immunity, (b) stimulating or enhancing an immune response, (c) treating a condition characterized by abnormal cell proliferation, (d) increasing cytokine and/or chemokine production, or (e) stimulating or enhancing production of T-cells, in a mammal, comprising administering to a mammal in need thereof an effective amount of a compound that inhibits a plurality of mammalian DASH serine proteases. For example, the compound that inhibits a plurality of mammalian DASH serine proteases may be t-butylGly-boroPro.

Claims (15)

1. A method of treating cancer, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound represented by:

2. The method of claim 1 , wherein the cancer is selected from the group consisting of basal cell carcinoma, biliary tract cancer, bladder cancer, bone cancer, brain cancer, breast cancer, cervical cancer, choriocarcinoma, CNS cancer, colon and rectum cancer, connective tissue cancer, cancer of the digestive system, endometrial cancer, esophageal cancer, eye cancer, cancer of the head and neck, gastric cancer, intra-epithelial neoplasm, kidney cancer, larynx cancer, leukemia, acute myeloid leukemia, acute lymphoid leukemia, chronic myeloid leukemia, chronic lymphoid leukemia, liver cancer, small cell lung cancer, non-small cell lung cancer, lymphoma, Hodgkin's lymphoma, Non-Hodgkin's lymphoma, melanoma, myeloma, neuroblastoma, oral cavity cancer, ovarian cancer, pancreatic cancer, prostate cancer, retinoblastoma, rhabdomyosarcoma, rectal cancer, renal cancer, cancer of the respiratory system, sarcoma, skin cancer, stomach cancer, testicular cancer, thyroid cancer, uterine cancer, and cancer of the urinary system.

3. The method of claim 1 , further comprising co-administering to the mammal a therapeutically effective amount of tumor-primed T-cells.

4. The method of claim 1 , further comprising co-administering to the mammal a therapeutically effective amount of a dendritic cell vaccine.

5. The method of claim 1 , further comprising treating the mammal with a second therapy selected from the group consisting of surgery, radiation and chemotherapy.

6. A method of increasing antitumor immunity in a mammal, comprising administering to a mammal in need thereof an effective amount of a compound represented by:

7. The method of claim 6 , wherein said antitumor immunity is increased for tumors selected from the group consisting of lung tumors, lymphomas, breast tumors, colorectal tumors, thyroid tumors, uterine tumors, pancreatic tumors, prostate tumors, skin tumors, kidney tumors, liver tumors and brain tumors.

8. A method of stimulating or enhancing an immune response in a mammal, comprising administering to a mammal in need thereof an effective amount of a compound represented by:

9. A method of treating a condition characterized by abnormal cell proliferation, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound represented by:

wherein:

the condition characterized by abnormal cell proliferation is a cancer, a blood vessel proliferative disorder, or a fibrotic disorder.

10. A method of increasing cytokine and/or chemokine production in a mammal, comprising administering to a mammal in need thereof an effective amount of a compound represented by:

11. A method of stimulating or enhancing production of T-cells in a mammal, wherein said T-cells recognize an antigen on a malignat cell, comprising administering to a mammal in need thereof an effective amount of a compound represented by:

12. The method of claim 11 , wherein said malignant cell is a carcinoma, sarcoma, leukemia, lymphoma or myeloma.

13. The method of claim 1 , wherein the mammal is a human.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jul 7, 2015
From: TUFTS UNIVERSITY BOSTON
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 036074/0400 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 1, 2014
From: BACHOVCHIN, WILLIAM W
To: TRUSTEES OF TUFTS COLLEGE
Reel/Frame 033222/0353 →
Continuity (2)
Provisional Application 61562497 · Nov 22, 2011
Related Publication 20140271725A1 · Sep 18, 2014